Patient-Reported Outcomes From the Phase 3 IMpassion031 Trial of Neoadjuvant Atezolizumab Plus Chemotherapy in Early Triple-Negative Breast Cancer

IMpassion031 is a global, Phase III, multicenter, double-blind, randomized, placebo-controlled study in patients with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadjuvant atezolizumab or placebo with nab-paclitaxel followed by atezolizumab or placebo with dose-dense doxorubicin + cyclophosphamide. Patient reported outcomes (PROs) of quality of life, physical and role function, and treatment-related symptoms were collected to comprehensively assess treatment burden from the patients’ perspective, inform clinical benefit and decision-making and address the lack of patient-reported data in this setting.